A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR

Oncogenic KRAS signaling plays a critical role in pancreatic ductal adenocarcinoma (PDAC) biology. Recent studies indicate that the combination of MEK and BCL-xL inhibition is synthetically lethal and holds promise for some types of solid cancers, however, patient response was poorly observed in PDA...

Full description

Saved in:
Bibliographic Details
Main Authors: Song Han, Gerik W. Tushoski-Alemán, Peiyi Zhang, Guangrong Zheng, Daohong Zhou, Zhiguang Huo, Jonathan Licht, Thomas J. George, Carmen Allegra, Jose G. Trevino, Steven J. Hughes
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
PDAC, Pancreatic Ductal Adenocarcinoma
EGFR, Epidermal Growth Factor Receptor
MEK, Mitogen-Activated Protein Kinase Kinase
KRAS, Kirsten Rat Sarcoma Viral Oncogene Homolog
Combinational targeting therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558624001118
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1476558624001118

Similar Items